Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
09:00am, Wednesday, 21'st Aug 2024
DehydraTECH-liraglutide is showing apparent superiority to DehydraTECH-semaglutide Select DehydraTECH-CBD formulations are showing apparent superiority to DehydraTECH-GLP-1 at 4 and 8 weeks KELOWNA, B
Hims & Hers Health: GLP-1 Is Not The Only Tailwind In This Growth Story
11:20pm, Tuesday, 20'th Aug 2024
Hims & Hers Health stock is up over 37% since my initial coverage, as the company is experiencing strong investor optimism from its compounded GLP-1 additions to its Weight Loss portfolio. The company
SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is rai
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company deve
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
06:12am, Sunday, 18'th Aug 2024
The anti-obesity market is a huge growth opportunity in healthcare. Novo Nordisk and Eli Lilly dominate it today, but it may not be long before there's more competition.
Eli Lilly's Top GLP-1 Drugs Now Account for Nearly 40% of Its Revenue, and That's Likely to Go Higher in Future Quarters
07:21am, Saturday, 17'th Aug 2024
Eli Lilly's sales grew by 36% last quarter, largely due to the success of two products. The company has a promising molecule, tirzepatide, which has shown that it can help people lose significant weig
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function
08:00am, Thursday, 15'th Aug 2024
TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI,
What Eli Lilly, Novo Nordisk earnings show about GLP-1 sales
01:07pm, Friday, 09'th Aug 2024
Recent earnings from Eli Lilly and Company (LLY) and Novo Nordisk (NVO) highlight the demand for GLP-1 drugs and why not all GLP-1 providers may be created equal. Yahoo Finance senior healthcare repor
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's he
Excitement grows around Eli Lilly's GLP-1 drugs in Q2 earnings
06:37pm, Thursday, 08'th Aug 2024
Shares of Eli Lilly (LLY) are jumping after the company posted second quarter earnings results, beating expectations on both the top and bottom lines. The pharmaceutical giant raised its revenue outlo
Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
09:23am, Wednesday, 07'th Aug 2024
Hims just reported record Revenue, Profits, and Cash Flows, signifying improving fundamentals. This was driven by robust growth in its core offerings as well as the launch of its new Weight Loss offer
Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
04:05pm, Tuesday, 06'th Aug 2024
- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity -
Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
08:00am, Tuesday, 06'th Aug 2024
MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative th
Hims & Hers Stock Is Looking to Cash in From the GLP-1 Hype, but Will Its Controversial Strategy Pay Off?
09:15am, Friday, 02'nd Aug 2024
Hims & Hers is offering customers access to compounded GLP-1 weight loss drugs. Compounded drugs are only available when there's a shortage.
Teva Pharma CEO: Majority of momentum came from innovative business, not GLP-1s
12:14pm, Wednesday, 31'st Jul 2024
Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss how much of the company's momentum is around its generic obesity drug, the market's excitement around its GLP-1 drug, and much more.
